Janux Therapeutics (JANX) Income from Continuing Operations (2020 - 2025)
Historic Income from Continuing Operations for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to -$24.3 million.
- Janux Therapeutics' Income from Continuing Operations rose 1335.04% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.9 million, marking a year-over-year decrease of 6832.13%. This contributed to the annual value of -$69.0 million for FY2024, which is 1835.73% down from last year.
- Latest data reveals that Janux Therapeutics reported Income from Continuing Operations of -$24.3 million as of Q3 2025, which was up 1335.04% from -$33.9 million recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Income from Continuing Operations ranged from a high of -$2.3 million in Q1 2021 and a low of -$33.9 million during Q2 2025
- In the last 5 years, Janux Therapeutics' Income from Continuing Operations had a median value of -$16.1 million in 2022 and averaged -$16.0 million.
- Its Income from Continuing Operations has fluctuated over the past 5 years, first tumbled by 75716.56% in 2021, then soared by 6596.41% in 2024.
- Janux Therapeutics' Income from Continuing Operations (Quarter) stood at -$13.4 million in 2021, then dropped by 19.75% to -$16.1 million in 2022, then increased by 26.81% to -$11.8 million in 2023, then crashed by 71.93% to -$20.2 million in 2024, then decreased by 20.27% to -$24.3 million in 2025.
- Its last three reported values are -$24.3 million in Q3 2025, -$33.9 million for Q2 2025, and -$23.5 million during Q1 2025.